Study of Phenethyl Isothiocyanate in Lymphoproliferative Disorders
Phase 1
Withdrawn
- Conditions
- LeukemiaLymphoproliferative Disorders
- Interventions
- Drug: Phenethyl Isothiocyanate (PEITC)
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2013-04-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00968461
Ex-Vivo Depletion of Myeloma Cells From Peripheral Blood Progenitor Cell Grafts
Phase 2
Withdrawn
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2013-04-05
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00968396
C-VISA BikDD: Liposome in Advanced Pancreatic Cancer
Phase 1
Withdrawn
- Conditions
- Pancreatic Cancer
- Interventions
- Genetic: BikDD Nanoparticle
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2019-04-11
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00968604
A Study for Leukemia Patients With Life-Threatening Infections
Phase 3
Completed
- Conditions
- Leukemia
- Interventions
- Procedure: White Blood Cell Transfusion
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2013-11-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 178
- Registration Number
- NCT00968838
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
Trial of Curcumin in Cutaneous T-cell Lymphoma Patients
Phase 2
Withdrawn
- Conditions
- Cutaneous T-cell Lymphoma
- Interventions
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2012-09-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00969085
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
Phase 2
Completed
- Conditions
- Acute Myelogenous LeukemiaMyelodysplastic Syndrome
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2013-03-08
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 71
- Registration Number
- NCT00968071
- Locations
- 🇺🇸
UT MD Anderson Cancer Center, Houston, Texas, United States
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 1
Completed
- Conditions
- Acute Lymphocytic LeukemiaLeukemia
- Interventions
- First Posted Date
- 2009-08-28
- Last Posted Date
- 2019-02-27
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT00968253
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.
Phase 2
Completed
- Conditions
- Recurrent Classic Hodgkin LymphomaRefractory Classic Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2020-04-20
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT00967369
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2015-02-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00967044
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple Myeloma
Phase 1
Completed
- Conditions
- Refractory Plasma Cell MyelomaRecurrent Plasma Cell Myeloma
- Interventions
- First Posted Date
- 2009-08-27
- Last Posted Date
- 2020-11-04
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 77
- Registration Number
- NCT00966693
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
© Copyright 2025. All Rights Reserved by MedPath